Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.

Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.

Recruitment to trials is known to be difficult. Previous research suggests that a crucial factor may be participants' difficulty with the concept of randomization. This study explored patients' perceptions of randomization and reasons for consent or refusal to participate in the ProtecT st...

Bibliografski detalji
Glavni autori:	Mills, N, Donovan, J, Smith, M, Jacoby, A, Neal, D, Hamdy, F
Format:	Journal article
Jezik:	English
Izdano:	2003

Slični predmeti

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study
od: J. Donovan, i dr.
Izdano: (2003-01-01)

Alcohol consumption and PSA-detected prostate cancer risk--a case-control nested in the ProtecT study.
od: Zuccolo, L, i dr.
Izdano: (2013)

Associations of adiponectin and leptin with stage and grade of PSA-detected prostate cancer: the ProtecT study.
od: Burton, A, i dr.
Izdano: (2013)

The ProtecT trial - Evaluating the effectiveness of treatment for clinically localised prostate cancer (ISRCTN20141297)
od: Lane, J, i dr.
Izdano: (2004)

Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies.
od: Lane, J, i dr.
Izdano: (2010)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study.
od: Rosario, D, i dr.
Izdano: (2012)

Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: Prospective evaluation within ProtecT study
od: Rosario, D, i dr.
Izdano: (2012)

The protecT (prostate testing for cancer and treatment) study: Evaluating screening and treatment of clinically localised prostate cancer in the UK
od: Hamdy, F, i dr.
Izdano: (2006)

A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
od: Mills, N, i dr.
Izdano: (2006)

Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT study.
od: Rosario, D, i dr.
Izdano: (2008)

The Prostate Testing for Cancer and Treatment (ProtecT) study: what have we learnt?
od: Hamdy, F
Izdano: (2017)

Association of obesity with prostate cancer: A case-control study within the population-based PSA testing phase of the ProtecT study
od: Dimitropoulou, P, i dr.
Izdano: (2011)

Association of obesity with prostate cancer: a case-control study within the population-based PSA testing phase of the ProtecT study.
od: Dimitropoulou, P, i dr.
Izdano: (2011)

Establishing nurse-led active surveillance for men with localised prostate cancer: development and formative evaluation of a model of care in the ProtecT trial
od: Wade, J, i dr.
Izdano: (2015)

Suitability of PSA-detected localised prostate cancers for focal therapy: experience from the ProtecT study.
od: Catto, J, i dr.
Izdano: (2011)

Suitability of PSA-detected localised prostate cancers for focal therapy: Experience from the ProtecT study
od: Catto, J, i dr.
Izdano: (2011)

Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
od: Adams, Charleen D., i dr.
Izdano: (2018)

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.
od: Murad, A, i dr.
Izdano: (2009)

A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study).
od: Murad, A, i dr.
Izdano: (2010)

Associations of aspirin, nonsteroidal anti-inflammatory drug and paracetamol use with PSA-detected prostate cancer: findings from a large, population-based, case-control study (the ProtecT study).
od: Murad, A, i dr.
Izdano: (2011)

Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial
od: Chris Metcalfe, i dr.
Izdano: (2020-09-01)

Who can best recruit to randomized trials? Randomized trial comparing surgeons and nurses recruiting patients to a trial of treatments for localized prostate cancer (the ProtecT study).
od: Donovan, J, i dr.
Izdano: (2003)

The ProtecT trial: Analysis of the patient cohort, baseline risk stratification and disease progression
od: Young, GJ, i dr.
Izdano: (2020)

Mortality among nen with advanced prostate cancer excluded from the ProtecT Trial
od: Johnston, T, i dr.
Izdano: (2016)

Glycemic equipoise
od: Sanjay Kalra, i dr.
Izdano: (2017-01-01)

Modelling the lifetime cost-effectiveness of radical prostatectomy, radiotherapy and active monitoring for men with clinically localised prostate cancer from median 10-year outcomes in the ProtecT randomised trial
od: S. Sanghera, i dr.
Izdano: (2020-10-01)

Associations of sexual dysfunction symptoms with PSA-detected localised and advanced prostate cancer: a case-control study nested within the UK population-based ProtecT (Prostate testing for cancer and Treatment) study.
od: Collin, S, i dr.
Izdano: (2009)

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.
od: Lane, A, i dr.
Izdano: (2016)

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial
od: Donovan, JL, i dr.
Izdano: (2017)

Post-diagnosis serum insulin-like growth factors in relation to dietary and lifestyle changes in the Prostate testing for cancer and Treatment (ProtecT) trial.
od: Er, V, i dr.
Izdano: (2017)

Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the protecT randomised controlled trial according to treatment received
od: Neal, D, i dr.
Izdano: (2019)

Equipoise in action: A qualitative synthesis of clinicians’ practices across six randomised controlled trials
od: Halliday, A, i dr.
Izdano: (2016)

Participation in a single-blinded pediatric therapeutic strategy study for juvenile idiopathic arthritis: are parents and patient-participants in equipoise?
od: Petra C. E. Hissink Muller, i dr.
Izdano: (2018-12-01)

Prostate cancer screening and management: Caution against over-interpreting the results of the latest study, ProtecT
od: Isaac Yi Kim
Izdano: (2023-07-01)

A partial defense of clinical equipoise
od: Scott D Gelfand
Izdano: (2019-04-01)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: The ProtecT three-arm RCT
od: Hamdy, FC, i dr.
Izdano: (2020)

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT
od: Freddie C Hamdy, i dr.
Izdano: (2020-08-01)

Equipoise and research in the current COVID-19 pandemic
od: Jill M. Pulley, i dr.
Izdano: (2021-01-01)

Conveying equipoise during recruitment for clinical trials: Qualitative synthesis of clinicians' practices across six randomised controlled trials.
od: Rooshenas, L, i dr.
Izdano: (2016)